Table 3.
Application of aptamers in clinical trials
| Aptamers | Targets | Phase | References |
|---|---|---|---|
| Macugen | VEGF | Approved | 168 |
| E10030 | PDGF | Phase III | 169 |
| AS1411 | Nucleolin | Phase II | 124 |
| ARC1779 | vWF | Phase II | 170 |
| NU172 | Thrombin | Phase II | 171 |
| NOX-A12 | SDF-1 | Phase II | 172 |
| NOX-E36 | MCP-1 | Phase II | 172 |
| NOX-H94 | Hepcidin | Phase I | 173 |
| ARC1905 | Complement component 5 (C5) | Phase II | 174 |
| REG1 | Coagulation factor IXa | Phase III | 175 |
| ARC19499 | Hemophilia | Phase I | 176 |